Weekly channel feed – Endpoints News

Weekly channel feed

Analyzing the Endpoints 100; ‘Most favored nation’ targets revealed; Biotech slump makes leases a liability; and more

Yesterday

What we know about ‘most favored nation’; GSK’s $1.2B MASH deal; Bayer details staff cuts; and more

Last week

Makary names Vinay Prasad CBER chief; Q1 earnings report; More on “Most Favored Nations"; and more

3 weeks ago

Earnings season continues; FDA delays PDUFA date; AACR recap; and more

4 weeks ago

Earnings season is upon us; Makary on rare disease; Startup is first to inject CRISPR in the brain; and more

5 weeks ago

Trump’s executive order on drug pricing; Pfizer drops oral obesity drug; Seed rounds at their lowest in years; and more

Last month

Biotech’s survival guide; What tariffs could mean for pharma; Congress pushes for $15B federal biotech investment; and more

Last month

Staff cuts sweep across FDA; Tariff rollout raises questions; The R&D 15 is back; and more

Last month

HHS cuts and more from DC; Lyndra winds down; 23andMe files for bankruptcy; and more

Last month

Teenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win, but shifts focus; Alnylam’s big moment; and more

2 months ago

Updates on health agency nominees; New data from Pfizer, Beam; MASH startup weighs IPO; and more

2 months ago

FDA and NIH nominees sail through Senate hearings; Tariffs’ early impact on drug manufacturing; AbbVie’s move into the obesity market; and more

2 months ago

The top 100 biotech investors; FDA vaccine meeting canceled; Can Bill Anderson save Bayer?; and more

2 months ago

Bourla praises Trump as RFK Jr. preps vaccine review; Will CRISPR matter?; Atomwise hires new CEO; and more

3 months ago

Updates from Washington; A trio of Big Pharma deals; What do recent share buybacks mean for M&A?; and more

3 months ago

Q4 earnings updates; Biogen details revised research strategy; RFK Jr. advances out of Senate committee; and more

3 months ago

RFK Jr. hearings leave key GOP senator “struggling”; Drugmakers report Q4 earnings; Leerink builds healthcare M&A team; and more

3 months ago

Biogen paring back research efforts; Will Chinese biotechs threaten US dominance?; What the new administration means for pharma ; and more

4 months ago

JPM's M&A Monday frenzy; Ozempic selected for IRA negotiations; Pfizer says it's back on track; and more

4 months ago

DNA edit leads to apparent cure in infant; CDER director to step down; More biotechs emerge with assets from China; and more

4 months ago

Neumora fails Ph3 depression study; Our review of 2024 megarounds; Pfizer cuts Sangamo pact; and more

4 months ago

2024's biopharma winners and losers; CagriSema falls short; Merck swings China GLP-1 deal; and more

5 months ago

The Endpoints 100 is back; Inside Isomorphic Labs; FDA adcomm discusses severe RSV cases; and more

5 months ago

Lilly beats Novo in weight loss; Apogee plots Dupixent challenge; Biosecure compromise coming?; and more

5 months ago

12 3 4 Next page Last page